BioMarin Pharmaceutical Inc. BMRN
61.42 USD -0.01 (-0.02%)
Regular-session close
61.42 0.00 0.00%
After hours · Nov 19, 4:56 PM ET
61.00 Day range 64.00
49.26 52-week range 70.98
- YTD
- +3.35%
- 1 year
- +16.86%
News
marketbeat.com BioMarin Pharmaceutical Bets on Amicus Growth as VOXZOGO Competition Concerns Mount BioMarin Pharmaceutical NASDAQ: BMRN is betting that a growing rare-disease pipeline and its integration of Amicus will help sustain growth, as executives seek to address investor concerns about…
seekingalpha.com BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies Global Healthcare Conference 2026 Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
marketbeat.com BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms BioMarin Pharmaceutical NASDAQ: BMRN expects growth from its acquired rare disease treatments, an expanded market for VOXZOGO and a pipeline that could deliver patient data in 2027, Chief Executive…
seekingalpha.com BioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 Transcriptbenzinga.com Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $103 Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $119 to $103.
benzinga.com JP Morgan Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $86 JP Morgan analyst Jessica Fye maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $87 to $86.
benzinga.com Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $119 Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $122 to $119.
benzinga.com Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $94 Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price target from $97 to $94.
benzinga.com HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and maintains $60 price target.
benzinga.com RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $60 RBC Capital analyst Luca Issi maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price target from $62 to $60.
benzinga.com Stifel Maintains Hold on BioMarin Pharmaceutical, Lowers Price Target to $66 Stifel analyst Paul Matteis maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Hold and lowers the price target from $70 to $66.
benzinga.com Biomarin Pharmaceutical Q3 2026 Earnings Call Transcript Biomarin Pharmaceutical (NASDAQ:BMRN) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Biomarin Pharmaceutical Q3 Adj. EPS $0.23 Beats $0.12 Estimate, Sales $1.025B Miss $1.026B Estimate Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.12 by 91.67 percent. This is a 91.67 percent increase over…
benzinga.com BioMarin Pharmaceutical Lowers FY2026 Adj EPS Guidance from $4.90-$5.10 to $2.80-$3.10 vs $3.32 Est; Lowers FY2026 Sales Guidance from $3.875B-$3.925B to $3.800B-$3.900B vs $3.918B Est BioMarin Pharmaceutical (NASDAQ:BMRN) lowers FY2026 Adj EPS guidance from $4.90-$5.10 to $2.80-$3.10 vs $3.32 analyst estimate. Lowers FY2026 sales outlook from $3.875 billion-$3.925 billion to…
benzinga.com BioMarin Pharmaceutical Enters License Agreement With GC Biopharma And Hanmi Pharm To Develop And Commercialize Its HM15421/GC1134A Investigational Long-Acting Enzyme Replacement Therapy For Fabry Disease; Company To Pay $70M Up Front, With Partners Eligible For Up To $405M In Milestones HM15421/GC1134A is a human recombinant alpha-galactosidase A (a-Gal A) enzyme therapy currently being studied in a Phase 1/2 clinical trial in people living with Fabry disease and has the potential…
benzinga.com Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122 Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $124 to $122.
benzinga.com Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $86 price target.
